Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mandie Pittman

Nurse Practitioner Milton, FL Nurse Practitioner

NPI 1922571843 CMS profile 10582370

5952 Berryhill Rd, Milton, FL 32570

Open in the dashboard

General payments

$3,812

202 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mandie Pittman of Milton, FL is reported in the CMS Open Payments database as having received $3,812 across 202 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $734 34
2024 General $1,737 91
2023 General $729 39
2022 General $600 37
2021 General $12 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mandie Pittman
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Mandie Pittman were reported at $734. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Mandie Pittman Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $12 $135 $40–$426 $132
2022 $600 $152 $48–$470 $149
2023 $729 $166 $54–$529 $160
2024 $1,737 $173 $55–$556 $164
2025 $734 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $710 54 payments
  2. Janssen Biotech, Inc. $452 18 payments
  3. Genzyme Corporation $333 17 payments
  4. Amgen Inc. $319 16 payments
  5. Pfizer Inc. $306 15 payments
  6. Dermavant Sciences, Inc. $255 17 payments
  7. Novartis Pharmaceuticals Corporation $252 13 payments
  8. Lilly USA, LLC $241 8 payments
  9. Regeneron Healthcare Solutions, Inc. $208 12 payments
  10. Sanofi-Aventis U.S. LLC $171 2 payments
  11. Other $565 30 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,328 196 payments
  2. Education $484 6 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $644 28 payments
  2. SKYRIZI $509 41 payments
  3. TREMFYA $452 18 payments
  4. Otezla $319 16 payments
  5. CIBINQO $306 15 payments
  6. VTAMA $271 20 payments
  7. DUPIXENT Inflammation And Immunology $176 10 payments
  8. LITFULO $145 10 payments
  9. EUCRISA $135 10 payments
  10. SOTYKTU $134 7 payments
  11. Other $1,060 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,314

Median for Nurse Practitioner: 389

Drug cost

$1,828,460

Median for Nurse Practitioner: $21,885

Branded share of claims

24%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 38 $807,684
Dupixent Pen Dupilumab Brand 155 $596,945
Humira(Cf) Pen Adalimumab Brand 17 $139,157
Cosentyx Sensoready (2 Pens) Secukinumab Brand 14 $132,481
Otezla Apremilast Brand 23 $123,845
Clobetasol Propionate Generic 103 $4,980
Ketoconazole Generic 273 $4,358
Pimecrolimus Generic 11 $3,839
Ammonium Lactate Generic 66 $1,984
Clobetasol Emollient Clobetasol Propionate/Emoll Brand 24 $1,881

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$114,884

Of which drugs: $56

Medicare patients

670

Average age 73

Services billed

3,923

339 women, 331 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 30%
Ischemic heart disease 24%
Chronic kidney disease 21%
Depression 19%
COPD 17%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 21 83 $53
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 12 60 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $305
$305 — —
DUPIXENT
  • GENZYME CORPORATION $142
  • Regeneron Healthcare Solutions, Inc. $78
  • SANOFI-AVENTIS U.S. LLC $72
$292 155 —
VTAMA
  • Dermavant Sciences, Inc. $255
$255 — —
SKYRIZI
  • AbbVie, Inc. $145
$145 38 —
Otezla
  • Amgen Inc. $133
$133 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

202 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record